Trubion was a publicly held biopharmaceutical company that was focused on creating a pipeline of protein-based therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer.

In December 2005, Trubion entered into a collaborative agreement with Wyeth[2] for the development and worldwide commercialization of CD20-directed therapeutics.

SMIP therapeutics are mono-specific (they recognize and attach to single antigen targets and initiate biological activity).

Trubion worked on SMIP drug candidates that targeted validated antigens with the same specificity and predictable biological activity as mAbs.

TRU-ADhanCe technology could be applied late in development to established manufacturing lines and generate candidates with increased ADCC and longer in vivo half lives.